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Intimate partner violence (IPV) is increasingly understood as an important public health 
issue. It is well understood that intimate partner violence has many negative effects on its 
survivors ranging from physical to mental health conditions. The population of people who 
experience intimate partner violence and population of pregnant women are both vulnerable 
populations. Examining the two populations together demands a trauma-informed approach and 
an understanding of the intricacies of both pregnancy and intimate partner violence. While IPV 
has been studied among the pregnant population, intimate partner violence as it relates to the 
maternal fetal medicine (MFM) or high-risk pregnancy population is not yet well understood. 
The purpose of this study is to describe the prevalence and effects of IPV among the MFM 
population at the Methodist Perinatal Center in Omaha, NE. This study analyzed secondary data 
obtained through the Abuse Assessment Screen (AAS) that was incorporated into the electronic 
medical record (EMR) at Methodist Perinatal Center. Data were input into SPSS from which 
descriptive statistics and a bivariate analysis (Chi square test) were entered. This study found that 
5.6% of patients at Methodist Perinatal Center have experienced IPV. Further, this study found 
that seven maternal and fetal health outcomes are associated with IPV including: BMI ≥25, STI, 
psychiatric disorder, birth weight < 2.499kg, ultrasound anomaly, non-employer-based insurance 
(self-pay and Medicaid), and non-married status These results show that it is important to screen 
for IPV in the high-risk pregnancy setting. As this study shows that IPV occurs and negatively 
affects women and their children, there is a need for further research on the effects of IPV and 





Chapter 1: Introduction 
Research Question and Aims 
The objective of this study is to determine the prevalence of intimate partner violence 
(IPV) among women with a high-risk pregnancy at the Methodist Perinatal Center in Omaha, 
NE.  IPV is defined as, “physical violence, sexual violence, stalking and psychological 
aggression (including coercive acts) by a current or former intimate partner,” (CDC, 2017b). The 
population being studied is the Maternal Fetal Medicine (MFM) obstetrics population. The MFM 
population consists of the high-risk pregnancy population. A high-risk pregnancy is “one that 
threatens the health or life of the woman or her fetus” (Society for Maternal Fetal Medicine, 
2018). The current medical literature on IPV in pregnancy has largely focused on low to average-
risk pregnancy. Since the literature on IPV in high-risk obstetrics populations is lacking, this 
study aims to determine just how prevalent it is for women to experience IPV during a high-risk 
pregnancy. Specifically, the primary research question is: what is the prevalence of IPV at the 
Methodist Perinatal Center? Secondary objectives for this study include examining the risk 
factors for IPV and whether the existing IPV is associated with adverse pregnancy outcomes 
and/or adverse fetal outcomes. 
Significance 
High risk pregnancies can be variable as some women are at an increased risk for 
complications before they become pregnant and some are identified as high risk as the pregnancy 
develops. Risk factors for high-risk pregnancy include pre-existing health conditions prior to 
pregnancy such as obesity, multiple gestations, HIV positive status, hypertension, teenage 
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pregnancy, advanced maternal age, or diabetes mellitus (Eunice Kennedy Shriver National 
Institute of Child Health and Human Development, 2017). The effects of IPV on pregnant 
women, including high-risk pregnant women, are varied and potentially life-threatening. 
According to the South Atlantic Association of Obstetricians and Gynecologists, IPV has many 
effects on a pregnant woman both physically and mentally including: bone fractures, lacerations 
and head trauma, sexually transmitted infections and unintended pregnancies, pain disorders, and 
higher rates of depression, anxiety, posttraumatic stress disorder, and suicide (Chisholm et al., 
2017a). Zachor et al. (2018) also report that IPV in pregnancy is associated with sexually 
transmitted infections, mental health disorders, pain disorders, gastrointestinal disorders, and 
small for gestational age infants. Additionally, Hossieni et al. (2017) found that women who 
experience IPV during pregnancy are at a higher risk of fearing birth. Adverse fetal outcomes 
include small for gestational age, preterm birth, and low birthweight. Additionally, in several 
parts of the United States, IPV can lead to suicide and homicide which are leading causes of 
pregnancy-associated mortality (Chisholm et al., 2017a). Clearly, IPV can have very serious, and 
potentially fatal, consequences for a pregnant woman and the developing fetus.  
One of the first reviews of the prevalence of IPV in pregnancy in the United States found 
the prevalence of IPV in pregnancy to be 0.9-20.1%; this wide range was interpreted to be due to 
variety in survey instrument, study population, and study methods (Gazmararian et al., 1996).  
Similarly, more recent estimates of the prevalence of IPV vary widely from 3-30% (Devries et 
al., 2010). Most studies report a range of 3.9-8.7% (Van Parys et al., 2014). More recently, a 
2009-2010 survey of women in a 30-state area found that the prevalence of IPV among the non-
MFM pregnant population was 3.2% (Chisholm et al., 2017a). In 2017, according to the CDC 
Pregnancy Risk Assessment Monitoring System (PRAMS), 2.2% of women experienced IPV 
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during pregnancy (CDC, 2017a). The PRAMS survey estimates IPV in pregnancy by asking two 
questions. Question one asks: “during your most recent pregnancy, did any of the following 
people push, hit, slap, kick, choke or physically hurt you in any other way?” Participants select 
my husband or partner, my ex-husband or ex-partner, another family member, and/or someone 
else. The second question asks, “during any of the following time periods, did your husband or 
partner threaten you, limit your activities against your will, or make you feel unsafe in any other 
way?” Participants are asked to indicate during the 12 months before I got pregnant, during my 
most recent pregnancy, and/or since my new baby was born (CDC, 2017a). Currently, there are 
no estimates as to the prevalence of IPV in the MFM population; this study aims to establish the 
prevalence at Methodist Women’s Hospital in Omaha, NE to establish a baseline prevalence 
upon which further research will contribute.   
Chapter 2: Background and Literature Review 
 A complete understanding of IPV requires a discussion of the prevalence of violence-
particularly IPV- in the United States. According to the National Intimate Partner and Sexual 
Violence survey, 1 in 3 women experience violence in their lifetime including 1 in 10 women 
being raped and 1 in 3 being physically abused (Breiding et al., 2011). Nearly 50% of women 
and men experience psychological abuse from an intimate partner (Anyikwa, 2016). For 
pregnant women, a 2009-2010 survey of women in a 30-state area found that the prevalence of 
IPV among the non-MFM pregnant population was 3.2% (Chisholm et al., 2017a).  
Further, women who experience IPV are exposed to trauma which occurs when 
maladaptive behaviors replace a person’s normal ways of coping based on a person’s experience 
of an event (Anyikwa, 2016). Therefore, when working with patients who have experienced IPV, 
it is important to consider trauma. The concept of a trauma-informed approach has existed in the 
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social work pedagogy for some time. A trauma-informed approach shifts from seeing behavior as 
pathological to recognizing behavior as “strengths-based” and emphasizes the resilience of 
survivors of IPV (Anyikwa, 2016, pg. 487). The goals of a trauma-informed approach and 
trauma-informed care (TIC) is to reduce symptoms and work with patients towards recovery 
(Anyikwa, 2016). The Substance Abuse and Mental Health Services Administration created a 
trauma-informed framework which operates based on four assumptions and six principles 
(Substance Abuse and Mental Health Services Administration, 2014). The assumptions are as 
follows: realization of trauma, recognition of trauma, response to trauma, and resisting re-
traumatization. The principles are: emotional and physical safety of the patient; trustworthiness 
and transparency; peer support; collaboration and mutuality; empowerment; voice and choice; 
and cultural, historical and gender issues (Anyikwa, 2016). When working with patients in any 
capacity, it is important to keep a trauma-informed approach in mind.  
Many studies have examined risk factors and predictors of IPV among pregnant women. 
Researchers in South Korea found several predictors of IPV such as unintended pregnancy, age, 
employment status, and the level of education (Lee et al., 2017). Another study found that among 
American women, an unplanned pregnancy and having parents with less than a high-school 
education (indicating a lower socioeconomic status) were risk factors for pregnant women 
experiencing IPV. This study found that older age and status as “married” were protective factors 
for IPV in pregnancy; in other words, younger women and single women are at higher risk for 
IPV (Yakubovich et al., 2018). According to the Behavioral Risk Factor Surveillance System, 
evidence exists that health disparities according to race/ethnicity, education, income, and age 
affect a person’s risk for experiencing IPV (Chisholm et al., 2017a). 
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Further, a meta-analysis examining multiple studies of IPV in pregnancy identified seven 
victim risk factors often examined in studies including: lifetime exposure to violence, alcohol 
abuse, abuse prior to pregnancy, single status, lower educational attainment, unwanted 
pregnancy, and low socioeconomic status (James et al., 2013). Five of the studies examined by 
the meta-analysis found additional risk factors for IPV in pregnancy including lack of social 
support, drug abuse, and race (James et al., 2013). The meta-analysis also identified two main 
perpetrator risk factors among the studies which included unintended pregnancy and alcohol 
abuse (James et al., 2013). One study examined past experiences of family violence with regard 
to future risk of experiencing IPV in pregnancy and found that women who experience violence 
perpetrated by their family members are at high risk for IPV during their pregnancy (Ludermir et 
al., 2017). As such, there is strong evidence in the literature that there are many risk factors for 
IPV in pregnancy as well as some evidence of risk factors for perpetrators of IPV. 
 An important subset of the literature surrounding IPV in pregnancy focuses on screening 
for IPV. Studies often examine what screening methods are most appropriate for IPV in 
pregnancy. According to The American Journal for Obstetrics and Gynecologists, screening is a 
method to identify a disease that has not yet been diagnosed in patients with no signs or 
symptoms (Chisholm et al., 2017b). In the pregnant population, the value of screening for IPV is 
emphasized to improve patient quality of life by way of reducing future violence and improving 
pregnancy outcomes (Chisholm et al., 2017b). All major health organizations that work in 
women’s health including the WHO, ACOG, the IOM, and the USPSTF recommend screening 
for IPV in pregnancy (Chisholm et al., 2017b).  
There are several screening methods for IPV including the HITS, Woman Abuse 
Screening Tool, HARK tool, and Abuse Assessment Screen, all of which have been used in 
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pregnant women (Chisholm et al., 2017b). The HITS survey was developed for outpatient 
clinical settings; HITS is an acronym standing for hits, insults, threatens, and screams. There are 
four questions which are answered on a five-point scale in while one equals never and five 
equals frequently. The survey asks: since you were pregnant, has a partner or ex-partner 
physically hurt you, insulted you fairly often, threatened you, or screamed at you fairly often? 
(Bailey, 2010). The Women Abuse Screening Tool (WAST) is an eight-question survey that 
address emotional, physical, and sexual abuse; each question has three possible responses scored 
0-2 with 0 being no tension, no difficult, never and 2 being a lot of tension, great difficulty, or 
often. A score of ≥4 suggests exposure to IPV (Brown et al., 1996; Fletcher et al, 2016). The 
HARK screen was adapted from the AAS and consists of 4 questions of self-report (yes or no) 
relating to IPV. There is no pregnancy-specific question in the HARK tool (Sohal et al., 2007; 
Fletcher et al., 2016).  
 Moreover, one study examined training of nurses to recognize IPV on an antepartum unit. 
This particular study showed that after training nurses to recognize IPV, knowledge of IPV and 
the protocol to follow increased and was well-received by the nursing staff (Bermele et al., 
2018). In another study, a training program for primary care providers was analyzed and showed 
that compared to no training, training providers about IPV increased provider communication 
about IPV (Zachor et al., 2018). Therefore, the literature reveals that training programs for all 
health care providers is effective and can increase screening for IPV in pregnancy. 
Effects of Intimate Partner Violence 
 The literature has established a myriad of effects of IPV on pregnant women. One study 
found that patients who experienced IPV during pregnancy were more likely to experience poor 
birth outcomes including preterm deliveries, low birth weight infants, and infants needing NICU 
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care (Chen et al., 2017). Another study among women in Ethiopia found an association between 
IPV and low birth weight of the infant (Laelago et al., 2017). Yet another study on the effects of 
IPV on breastfeeding found that women who reported IPV during pregnancy were less likely to 
continue to breastfeed more than six weeks postpartum (Miller- Graff et al., 2018). Overall, it is 
clear from the studies reviewed that several forms of poor birth outcomes are associated with 
IPV during pregnancy, further bolstering the need to screen for and prevent IPV in pregnancy. 
 There is conclusive evidence that IPV during pregnancy is a very serious phenomenon 
affecting many women worldwide. Not only has research identified IPV in pregnancy as an issue 
worthy of further research, but there is also adequate evidence that there are many well-identified 
negative effects of IPV in pregnancy (Chisholm et al., 2017a; Zachor et al., 2018; Chen et al., 
2017; Laelago et al, 2017). It has been shown that standardized, routine clinical assessment is 
important to intervene in current abuse and, potentially, prevent future abuse (McFarlane et al., 
1992). Additionally, there is evidence that screening for IPV in pregnancy is beneficial and that 
there are several tools available for effective screening of IPV in pregnancy (Chisholm et al., 
2017b; Macfarlane et al., 1992; Van Parys et al., 2017; Webster et al., 2017; O’Reilly et al., 
2010). Furthermore, several training programs have provided increased screening for IPV in 
pregnancy by all members of the health care team. Finally, there have been many studies 
examining the negative birth outcomes related to IPV during pregnancy.  
However, further research is needed to determine how common the issue of IPV is among 
the high-risk obstetrics population as current medical research on IPV among the MFM 
population is lacking. It is reasonable to hypothesize that the addition of another risk factor for 
adverse pregnancy outcomes such as IPV to an already high-risk pregnancy would likely 
increase that high-risk pregnancy’s risk for adverse outcomes. Unfortunately, the medical 
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literature has yet to examine this hypothesis in depth. This study aims to fill this gap in the 
literature. 
This project will most benefit women, pregnant women, and high-risk obstetrics populations. 
The accumulation of these populations would account for almost every woman during her 
lifetime should she decide to or be able to reproduce. The population estimate of Omaha, NE 
during the study was 468, 262. As such, this study could potentially affect approximately 50% of 
the population in Omaha or approximately 230,000 women (United States Census Bureau, 
2017). More specifically this study focuses on pregnant women. According to Life Course 
Theory, any study involving women, such as this one, has the ability to be interpreted through a 
wide lens. Life Course Theory “refers to the sequence of events and roles- age-graded, socially 
defined, and nested within historical time and place- that forms our individual biographies,” 
(Kotch, 2013, pg. 68). There are three key concepts in life course theory: trajectories, transitions, 
and turning points. Trajectories describe health and well-being for a substantial period of a 
person’s life. Transitions are phases that are often associated with a change in health status and 
often occur over a brief time period. Turning points are changes in trajectories through changes 
in behavior or situation (Kotch, 2013). Pregnancy is a very common transition in a person’s life 
that can positively or negatively alter that person’s trajectory. From a life course perspective, the 
impact of this study is quite broad as the principle of life span development takes into account 
the cumulative effect of health over a person’s lifetime as well as generational effects (Kotch, 
2013). Additionally, this study’s findings impact the entire population as a whole as pregnant 
women generate the next generation of a society.  
The primary goal of this study is to estimate baseline data on the prevalence of IPV in a high-
risk obstetrics population. A literature review was performed in PubMed, EBSCO, and Google 
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Scholar searching for the prevalence of IPV in the MFM population using the search terms 
“intimate partner violence” and “maternal fetal medicine” and “high-risk pregnancy” and yielded 
no results; based on a search of the current literature, there are no current estimates of the 
prevalence of IPV in the MFM population. The secondary aim is to determine whether the IPV 
that exists causes adverse pregnancy outcomes and/or poor birth outcomes. The long-term goal 
would be to determine the adverse effects of IPV on high-risk pregnant women and finally how 
to intervene and prevent women from experiencing IPV in pregnancy or how to intervene as IPV 
is occurring. Only then could intervention efforts be undertaken. Indeed, research has shown 
empowerment intervention to be evidence-based in decreasing violence among the pregnant 
population over time (Chisholm et al., 2017b). This study will provide valuable knowledge about 
a vulnerable population, high-risk obstetrics, that will inform future scholarship that will lead to 
lasting change regarding the prevalence of IPV. Specifically, the questions for this study are: 
Research Question 1: What is the prevalence of IPV in a high-risk obstetrics population? 
Research Question 2: Is IPV associated with adverse pregnancy outcomes and/or poor birth 
outcomes? 
Chapter 3: Data and Methods 
Study Design, Setting, and Study Population 
This study is a retrospective cross-sectional study. A cross-sectional study fits this 
research question best as the study seeks to determine how many women are affected by IPV at 
one hospital in Omaha, NE. The Methodist Perinatal Center started screening every patient at 
their first obstetrics visit for IPV in January 2019 using the Abuse Assessment Screen. The 
population of this study was the Maternal Fetal Medicine (MFM) obstetrics population at the 
Methodist Perinatal Center at Methodist Women’s Hospital. The population for the current study 
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consists of 1,069 patients who presented for their first obstetrics visit at Methodist Women’s 
Hospital in Omaha, NE from January 2, 2019 to July 31, 2019.  
The study sample was obtained by convenience sampling due to the sensitive nature of 
the issue and the care health care workers must take when approaching the subject of IPV with 
participants. It would be unwise if not unethical to screen participants for IPV in a less structured 
environment with no access to resources. Specifically, since this is a clinical study, privacy and 
HIPAA laws were followed. Further, according to the CDC Pregnancy Risk Assessment 
Monitoring System (PRAMS), 2.2% of women experience IPV during pregnancy (CDC, 2017a). 
For a sample size of 1,281 patients, the confidence interval is +/- 0.08 meaning that we expected 
to find 1.4-3% of the patients included in this study to report positive for IPV.  
A survey has been chosen as the measurement instrument as it provides more data in a 
shorter amount of time than other instruments, such as qualitative interviews. The incorporation 
of the screening into the normal clinic flow created access to as many participants as possible. 
The method is also in line with past scholarship that has shown that a clinical provider 
performing a simple screen with no partner present is effective in identifying patients who have 
experienced IPV (McFarlane et al., 1992). 
Variables and Operational Definitions 
The primary outcome variable studied is intimate partner violence (IPV). The 
independent variables include insurance provider, race, ethnicity, socioeconomic status, and 
marital status. All of these factors could potentially affect a person’s risk for experiencing IPV. 
Additionally, the control variable is age which restricted the study to patients age 19 and above. 
In the state of Nebraska, the age of majority is 19; restricting children as study participants 
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simplifies study design. The study population was restricted to patients at Methodist Women’s 
Perinatal Center as that is the hospital where the survey was be administered.  
Next, a potential confounding variable is participant understanding of “abuse” in the first 
question of the survey: “Have you ever been physically or emotionally abused by your partner or 
someone important to you?” The word abuse itself is open to interpretation as there was no 
definition of abuse provided for the patient in the survey. The rest of the questions only focused 
on physical abuse and behavior. Patients’ determination on whether or not they had experienced 
IPV may have been influenced by these limitations. A last difficulty of this type of screening is 
that staff were not trained specifically on how to ask questions and to respond to patients if they 
had questions about the survey. If participants had questions, the responses they received might 
have varied according to the ability level of staff. 
Inclusion criteria included: women over the age of 19 and patients presenting for a first 
obstetrics visit at the clinic. Exclusion criteria included patients under the age of 19, patients with 
a triplet birth, and patients screened with the previously-used one-question screen. Patients under 
age 19 were excluded as they are minors in Nebraska and this study was focused on adult high-
risk obstetrics patients. Patients with triplet births were excluded as their outcomes are very 
different from singleton and twin births. Patients screened with the previously-used one-question 
screen were excluded as that was not the survey instrument being used in this study. 
Data Sources and Measurement 
The dependent variable, IPV, was measured by the Abuse Assessment Screen (AAS). 
The Abuse Assessment Screen has been used widely in the pregnant population to screen for IPV 
and is the standard survey method for IPV in the field of obstetrics (Chisholm et al., 2017a). The 
AAS has a sensitivity and specificity of 93-94% and 55-99%, respectively (Chisholm et al., 
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2017b; Zachor et al., 2018). The AAS is a confidential, anonymous five-question survey that was 
developed by McFarlane et al. (1992) to screen for IPV among the pregnant population. The 
questions are as follows: 
Question 1: “Have you ever been emotionally or physically abused by your partner or 
someone important to you?” 
Question 2: “Within the last year, have you been hit, slapped, kicked, or otherwise 
physically hurt by someone?” 
If the answer to question 2 is yes, the participant is prompted to select who the perpetrator of 
violence is such as a husband, ex-husband, boyfriend, stranger, other, or multiple and then how 
many times that violence occurred.  
Question 3: “Since you’ve been pregnant, have you been hit, slapped, kicked, or 
otherwise physically hurt by someone?” 
If the answer to question 3 is yes, the participant is again prompted to select what relationship 
they had to the perpetrator and how many times that violence occurred, to mark the area of injury 
on a body map, and to score each incident using a 1-6 scale of severity with ‘one’ being threats 
of abuse including the use of a weapon and ‘six’ being use of a weapon or wound from a 
weapon.  
Question 4: “Within the last year, has anyone forced you to have sexual activities?” 
Patients are asked to specify by whom and how many times the forced sexual activities occurred. 
Question 5: “Are you afraid of your partner or anyone you listed above?” (McFarlane et 
al., 1992, p. 3177) 
If a patient answers yes to any of the five questions, their response is recorded as positive for 
IPV. The AAS is relatively short, thereby reducing survey fatigue. The survey also utilizes non-
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judgmental language which is a key tenet of trauma-informed care. In addition to the AAS, 
deidentified demographic data from the electronic medical record was included in the data 
review. This additional data included maternal health outcomes, fetal health outcomes, insurance 
status (individual private pay, self-pay, or Medicare/Medicaid), employment status, age, 
language, race, ethnicity, and marital status.  
Furthermore, research question two asked: is IPV associated with adverse pregnancy 
outcomes and/or poor birth outcomes? To answer research question two, the maternal health 
outcomes that were examined were: preterm bleeding (PTB), maternal infection, preterm labor 
(PTL), mode of delivery, progress of labor, premature rupture of membranes (PROM), preterm 
premature rupture of membranes (PPROM), hospitalization before delivery, body mass index 
(BMI), anemia, bone fracture, laceration, head trauma, sexually transmitted infection (STI), pain 
disorder (chronic pain disorder, fibromyalgia, and endometriosis), and psychiatric disorder 
(depression, anxiety, panic disorder, and PTSD). Fetal outcomes that were examined are birth 
weight, gestational age, admission to a neonatal intensive care unit (NICU), APGAR scores at 
one and five minutes after birth, and breastfeeding status. Birth weight was recorded as birth 
weight A and B as twin births were included. For singleton births, birth weight A represents the 
birth weight of the single neonate. For twin births, birth weight A and B represented birth weight 
for baby A and baby B, respectively. Pregnancy conditions that were examined were: high risk 
pregnancy (HRP), ultrasound abnormality (polyhydramnios and oligohydramnios), fetal anomaly 
(chromosomal/genetic abnormalities, congenital heart disease), intrauterine growth restriction 
(IUGR), gestational diabetes mellitus (GDM), intrauterine fetal demise (IUFD), spontaneous 
abortion (SAB), hypertensive disorders of pregnancy (HTN DOP), history of SAB, history of 
IUFD, history of HTN DOP, history of cesarean delivery (CD), other substance use (alcohol and 
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illicit drug use), tobacco use, clotting disorder, seizure disorder, cardiac disease, renal disease, 
thyroid disease, chronic hypertension (HTN), and diabetes mellitus (DM) which includes both 
Type 1 and Type 2 diabetes. 
Table of Abbreviations 
PTB Preterm bleeding 
PTL Preterm labor 
PROM Premature rupture of membranes 
PPROM Preterm premature rupture of membranes 
BMI Body mass index 
STI Sexually transmitted infection 
NICU Neonatal intensive care unit 
HRP High risk pregnancy 
IUGR Intrauterine growth restriction 
GDM Gestational diabetes mellitus 
IUFD Intrauterine fetal demise 
SAB Spontaneous abortion 
HTN DOP Hypertensive disorders of pregnancy 
CD Cesarean delivery 
HTN Hypertension 






The size of the population of interest was 1,069. The sample size consisted of 967 patients 
who met initial inclusion criteria. Then, 218 patients with missing delivery data were excluded. 
Missing delivery data is defined as patients who delivered elsewhere, had not yet delivered, 
and/or patients with incomplete delivery data in the EMR. After exclusion, the sample size was 
749. Convenience sampling was achieved by collecting data from only one clinic. This also 
limited time and personnel constrains as including other hospitals would require the participation 
and cooperation from multiple departments and personnel, which is currently not feasible. As 
this study is estimating prevalence among all patients who fulfilled the inclusion criteria, it was 
not necessary to perform a power analysis.  
 
Data Collection 
IRB approval was obtained from Methodist Women’s Hospital August 29, 2019, and 
from UNMC on September 20, 2019. Every new patient presenting to the maternal fetal 
medicine clinic at Methodist Women’s Hospital in Omaha, NE for a first trimester obstetrics 
visit was screened for IPV using the Abuse Assessment Screen survey. The AAS was integrated 
into the electronic medical record and administered by nursing staff in a separate intake room at 
the Methodist Perinatal Center starting January 1, 2019 and continuing until July 31, 2019. 
Clinic staff asked the five AAS questions at the time of the patient visit; this data was then 
reviewed in the electronic medical record. Every patient seeking care for a first trimester 
obstetrics visit at the Perinatal Center at Methodist Women’s Hospital was screened. 
This research was carried out following established ethical protocols. For example, 
according to the SAMHSA trauma-informed framework, the principle of safety was emphasized 
(Substance Abuse and Mental Health Services Administration, 2014). Per protocol, no family, 
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friends, or significant others were allowed in the room at the time of screening to ensure 
confidentiality. However, some patients had a support person in the room while the AAS was 
administered; when this happened, the AAS questions were not asked. As a result, a third of 
participants were not screened. The principles of trustworthiness and transparency were also 
utilized; the clinic staff administering the screen were consistent and transparent with the 
patients. The principles of collaboration and mutuality were also a part of the process. The clinic 
staff have been trained in the era of recognizing patient autonomy which ensures that patients are 
seen as experts in their own lives (Anyikwa, 2016). This screening was incorporated into the 
regular clinic flow which assists to normalize the information being ascertained and attempts to 
make the patients more at ease when answering sensitive questions. As stated earlier, a positive 
screen was defined as the patient answering “yes” to any one of the five questions as has been 
established in standard usage of the AAS (Zachor et al., 2018). If patients screened positive, staff 
were instructed to provide clinical support and access to local resources such as the Women’s 




Prior to data analysis, all patient information was de-identified. Summary statistics were 
used to describe the frequency of variables and mean and standard deviation of the numerical 
variables. A bivariate analysis was conducted to look for a relationship between IPV and any of 
the independent variables. Chi-square tests were used to test for an association between IPV and 
categorical independent variables. Independent t tests were run for age and BMI. For this study, 
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IBM SPSS Statistics Subscription build number 1.0.0.1327 was utilized to perform the statistical 
analyses (IBM SPSS Statistics for Macintosh, 2018).  
Chapter 4: Results 
Demographic Data 
Table 1 includes demographic information including: insurance provider, language, race, 
ethnicity, marital status, employment, age, and body mass index (BMI). There are two missing 
variables for BMI as the BMI was incorrectly recorded for two patients; these values were 
265.15 and 154.86 which were excluded. Body mass index was divided into patients with a 
BMI≥25 or BMI<25 as a BMI that is greater than or equal to 25 is defined as overweight or 
obese. This cutoff was chosen as it is clinically significant to be either a healthy weight or 
overweight/obese. For age, an age greater than or equal to 35 is defined as advanced maternal 
age. These cutoffs were reasoned to be clinically significant. 
Table 1: Background Data (N=967) 
Variable N (%) Mean (SD) 
Race 
Asian 27 (2.8)  
American Indian/Alaskan Native 8 (0.8)  
Black 44 (4.6)  
Multiple 40 (4.1)  
Other 25 (2.6)  
White 816 (84.4)  
Unknown 7 (0.7)  
Ethnicity 
Hispanic 60 (6.2)  
Multiple 17 (1.8)  
Non-Hispanic 864 (89.3)  
Other 1 (0.1)  
Unknown 25 (2.6)  
Preferred Language for Healthcare Information Delivery 
Arabic 1 (0.1)  
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English 943 (97.5)  
French 1 (0.1)  
Other 5 (0.5)  
Russian 2 (0.2)  
Spanish 10 (1)  
Vietnamese 2 (0.2)  
Unknown 3 (0.3)  
Marital Status 
Divorced 24 (2.5)  
Married 734 (75.9)  
Single 195 (20.2)  
Unknown 14 (1.4)  
Insurance Provider 
Employer-Based Health Insurance 776 (80.2)  
Medicaid 177 (18.3)  
Self-pay 14 (1.4)  
Employment 
Employed 757 (78.3)  
Unemployed 201 (20.8)  
Unknown 9 (0.9)  
Age*  32.15 (5.29)  
<35yo 461 (61.5)  
≥35yo 288 (38.5)  
BMI*  29.42 (8.03)  
BMI <25 265 (35.5)  
BMI ≥25 484 (64.5)  
Missing 2 (0.3)  
*N=749 
 
Demographic Data After Exclusion of Missing Delivery Data 
Table 2 is a summary of demographic information after exclusion of patients with 
missing delivery data. In this table, the demographic data is split into two groups per variable 
based on the group with the highest percentage of patients. For insurance provider, patients were 
split into employer-based health insurance (EBHI) or non-employer-based health insurance. 
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Language was divided into English and Non-English. Race was split into White and Non-White. 
Ethnicity was split into Hispanic and Non-Hispanic. Marriage status was split into married and 
non-married. The demographic data was split into two groups at this stage to allow for larger 
group sample sizes. There was no missing demographic data after exclusion of patients with 
missing delivery data. 
Table 2: Demographics After Exclusion of Missing Delivery Data  
N=749 N (%) 
Race 
White 642 (85.7) 
Non-White 107 (14.3) 
Ethnicity 
Hispanic 693 (92.5) 
Non-Hispanic 56 (7.5) 
Preferred Language for Healthcare Information Delivery 
English 732 (97.7) 
Non-English 17 (2.3) 
Marriage Status 
Married 607 (81) 
Non-married 142 (19) 
Insurance Provider 
EBHI 626 (83.6) 
Non-EBHI 123 (16.4) 
  





Descriptive data that was collected included frequencies of all variables and demographic 
data. Patients with missing recorded delivery data likely only saw the MFM clinic for a consult 
or delivered somewhere other than Methodist Women’s Hospital. The missing data column 
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consists of patients with an AAS screen marked “unable to answer” which typically meant 
someone other than the staff member and the patient was in the room. 
Fetal Outcomes Before Exclusion of Patients with Missing Delivery Data 
Table 3 includes the mean and standard deviation for fetal outcomes before exclusion of 
patients with missing delivery data. Each variable was divided into two groups for bivariate 
analysis based on clinical reasoning. For birth weight, low birth weight is designated as less than 
2.499kg. For gestational age, a gestational age < 37 weeks is defined as preterm. For APGARs, 
an APGAR of 5 was chosen as the distinction as that is clinically significant. All of these cutoffs 
were reasoned to be clinically significant. Birth Weight was separated into birth weight A and B 
as there were 67 twins recorded. For all births that were singletons, birth weight A is the 
recorded weight for the singleton neonate. There are 900 missing values for Birth Weight B and 
APGAR B1 and B5 as there were only 67 twins total. From Table 3, it is evident that most 
patients gave birth at term to neonates of a normal birthweight with healthy APGAR scores. Of 
note, baby B of a twin pair tended to have a lower birth weight and APGAR than baby A of twin 
pairs. Table 4 includes fetal outcomes after exclusion of patients with missing delivery data.  
Table 3: Fetal Outcomes Before Exclusion of Patients with 
Missing Delivery Data  
Mean (SD) 
Birth Weight A (kg) n = 746 3.14 (0.74) 
Birth Weight B (kg) n = 67 2.12 (0.75) 
APGAR A1 n = 744 7.71 (1.63) 
APGAR A5 n = 744 8.69 (1.39) 
APGAR B1 n = 65 6.05 (2.85) 
APGAR B5 n = 65 7.52 (2.49) 
Gestational Age (GA) n=761 37.18 (4.07)   
 
Fetal Outcomes After Exclusion of Patients with Missing Delivery Data 
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Table 4: Fetal Outcomes After Exclusion of Patients 
with Missing Delivery Data 
N= 749 N (%) 
BWA ≥2.499 631(85) 
BWA<2.499 111(15) 
Missing 7 (0.9)   
BWB ≥2.499 23 (34.3) 
BWB<2.499 44 (65.7) 
Missing (Singleton births) 682 (91.1)   
GA ≥37 594 (79.3) 
GA<37 155 (20.7) 
Missing 0 
  
APGARA1 ≥5 697 (93.8) 
APGARA1<5 46 (6.2) 
Missing 6 (0.8)   
APGARA5 ≥5 726 (97.7) 
APGARA<5 17 (2.3) 
Missing 6 (0.8)   
APGARB1≥5 49 (75.4) 
APGARB1<5 16 (24.6) 
Missing (Singleton births) 684 (91.3)   
APGARB5≥5 54 (83.1) 
APGARB5<5 11 (16.9) 





Table 5 includes delivery outcomes including: mode of delivery data broken down into 
spontaneous vaginal delivery (SVD), operative vaginal delivery (OVD), primary cesarean 
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delivery (PCD), repeat cesarean delivery (RCD), and dilation and evacuation (D&E) for 
spontaneous abortions and intrauterine fetal demise. Table 5 also provides data for normal and 
abnormal progress of labor. Abnormal labor is defined as the abnormal progression of labor; 
abnormal progression of labor is defined as the observation of one of two abnormal labor 
patterns (protraction or arrest disorder) (Casanova et al., 2019); abnormal progress of labor was 
indicated by a record in the chart of prolongation of stage 2 of delivery. 
Table 5: Delivery Outcomes 
 (N=967) N (%) 
Spontaneous Vaginal Delivery 967 (42.1) 
Operative Vaginal Delivery 30 (3.1) 
Primary Cesarean Delivery 153 (15.8) 
Repeat Cesarean Delivery 160 (16.5) 
Dilation and Evacuation 10.0 (1.0) 
Mode of Delivery (Missing) 207 (21.4) 
Normal Progress of Labor 414 (42.8) 
Abnormal Progress of Labor 63 (6.5) 
Progress of Labor (Missing) 490 (50.7) 
 
Delivery Data After Exclusion of Missing Delivery Data 
Table 6 includes delivery and progress of labor data after exclusion of patients with 
missing delivery data. Patients were split into two groups at this stage for optimal data analysis. 
For delivery data, patients were recorded as vaginal or cesarean delivery. Progress of labor was 
recorded as normal or abnormal. Progress of labor is defined as abnormal if one of two abnormal 
labor patterns (protraction or arrest disorder) are observed (Casanova et al., 2019). This table 
shows no missing method of delivery. The missing progress of labor variable includes both 
cesarean deliveries wherein progress of labor does not apply and patients whose charts did not 
indicate progress of labor.  




N (%) N=749 
Vaginal Delivery 437 (58.3) 
Cesarean Delivery 312 (41.7) 
Progress of Labor (Normal) 410 (86.7) 
Progress of Labor (Abnormal) 63 (13.3) 
Progress of Labor (Missing) 276 (36.8) 
 
Pregnancy Condition Variables Before and After Exclusion of Patients with Missing 
Delivery Data  
Table 7 includes the 21 pregnancy condition variables that were recorded before and after 
exclusion of patients with missing delivery data. After exclusion of patients with missing 
delivery data, there were no missing values. 
Table 7: Pregnancy Condition Variables Before and After Exclusion of Patients with Missing 
Delivery Data 
 Before Exclusion (N=967) After Exclusion (N=749) 
Pregnancy 
Condition 
Yes N (%) No N (%) Yes N (%) No N (%) Missing 
High Risk Pregnancy 422 (43.6) 545 (56.4) 282 (37.7) 467 (62.3) 0 
Ultrasound Anomaly 104 (10.8) 863 (89.2) 84 (11.2) 665 (88.8) 0 
Fetal Anomaly 83 (8.6) 884 (91.4) 62 (8.3) 687 (91.7) 0 
Intrauterine Growth 
Restriction 
65 (6.7) 902 (93.3) 53 (7.1) 696 (92.9) 0 
Gestational 
Diabetes Mellitus 
90 (9.3) 877 (90.7) 77 (10.3) 672 (89.7) 0 
Intrauterine Fetal 
Demise 
8 (0.8) 959 (99.2) 6 (0.8) 743 (99.2) 0 
Spontaneous 
Abortion 



















52 (5.4) 915 (94.6) 46 (6.1) 703 (93.9) 0 
History of Cesarean 
Delivery 
194 (20.1) 773 (79.9) 172 (23) 577 (77) 0 
Other Substance 
Use 
9 (0.9) 958 (99.1) 5 (0.7) 744 (99.3) 0 
Tobacco Use 50 (5.2) 917 (94.8) 36 (4.8) 713 (95.2) 0 
Clotting Disorder 39 (4) 928 (96) 32 (4.3) 717 (95.7) 0 
Seizure Disorder 9 (0.9) 958 (99.1) 7 (0.9) 742 (99.1) 0 
Cardiac Disease 10.0 (1.0) 957 (99) 8 (1.1) 741 (98.9) 0 
Renal Disease 10.0 (1.0) 957 (99) 7 (0.9) 742 (99.1) 0 
Thyroid Disease 110 (11.4) 857 (88.6) 91 (12.2) 658 (87.9) 0 
Chronic 
Hypertension 
68 (7) 899 (93) 53 (7.1) 696 (92.9) 0 
Diabetes Mellitus 24 (2.5) 943 (97.5) 20 (2.7)  729 (97.3) 0 
 
Maternal and Fetal Health Outcomes 
Table 8 includes pregnancy outcomes and fetal health outcomes. Pregnancy outcomes 
include preterm bleeding (PTB), maternal infection, preterm labor (PTL), premature rupture of 
membranes (PROM), preterm premature rupture of membranes (PPROM), hospitalization before 
delivery, anemia, bone fracture, laceration, head trauma, sexually transmitted infection, pain 
disorder, psychiatric disorder, and multiple births. Patients with missing delivery data likely 
delivered somewhere other than Methodist Women’s Hospital, had not yet delivered, or had 
incomplete delivery data entered into the EMR. Table 8 fetal outcome data includes neonatal 
intensive care unit (NICU) admission and breastfeeding status. 
Table 8: Maternal and Fetal Health Outcomes  
Pregnancy 
Outcomes 
Before Exclusion (N=967) After Exclusion (N=749) 
Yes N (%)  No N (%)  Missing N 
(%)  
Yes N (%) No N (%)  Missing N 
(%)  





11 (1.1) 758 (78.4) 198 (20.5) 10 (1.3) 739 (98.7) 0 (0) 
PTL 64 (6.6) 705 (72.9) 198 (20.5) 58 (7.7) 691 (92.3) 0 (0) 
PROM 5 (0.5) 759 (78.5) 203 (21) 5 (0.7) 744 (99.3) 0 (0) 
PPROM 36 (3.7) 728 (75.3) 203 (21) 35 (4.7) 714 (95.3) 0 (0) 
Hospitalization 
Before Delivery 
145 (15) 624 (64.5) 198 (20.5) 141 (18.8) 608 (81.2) 0 (0) 
Anemia 58 (6) 882 (91.2) 27 (2.8) 54 (7.2) 695 (92.8) 0 (0) 
Bone Fracture 0 (0) 940 (97.2) 27 (2.8) 0 (0) 749 (0) 0 (0) 
Laceration 2 (0.2) 938 (97) 27 (2.8) 2 (0.3) 747 (99.7) 0 (0) 
Head Trauma 2 (0.2) 938 (97) 27 (2.8) 2 (0.3) 747 (99.7) 0 (0) 
STI 42 (4.3) 892 (92.9) 26 (2.8) 34 (4.5) 715 (95.5) 0 (0) 
Pain Disorder 49 (5.1) 892 (92.2) 26 (2.7) 45 (6) 704 (94) 0 (0) 
Psychiatric 
Disorder 
186 (19.2) 757 (78.3) 24 (2.5) 151 (20.2) 598 (79.8) 0 (0) 
Multiples 76 (7.9) 883 (91.3) 8 (0.8) 69 (9.2) 680 (90.8) 0 (0) 
NICU 158 (16.3) 583 (60.3) 226 (23.4 157 (21.3) 580 (78.7) 12 (1.6) 
Breastfeeding 650 (67.2) 43 (4.4) 274 (28.3) 648 (94) 41 (6) 60 (8) 
 
Prevalence of Intimate Partner Violence 
Table 9 provides data for the prevalence of IPV. Patients who answered yes to any of the 
five AAS questions were recorded as positive for having experienced IPV. The missing data 
column consists of patients with an AAS screen marked “unable to answer” which typically 
meant someone other than the staff member and patient was in the room. As noted earlier, 
around a third of patients were not able to be screened for IPV. Research question one asked 
what is the prevalence of IPV in a high-risk obstetrics population? According to this study, 5.6% 
+/- 1.45% (4.09%-7.1%) of high-risk obstetrics patients at Methodist Women’s Hospital have 
experienced IPV. 
Table 9: Prevalence of Intimate Partner Violence 
IP
V
 Before Exclusion (N=967) After Exclusion (N=749) 
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Yes N (%) No N (%) Missing N (%) Yes N (%) No N (%) Missing N (%) 
54 (5.6) 587 (60.7) 326 (33.7) 35 (7.8) 413 (55.1) 301 (40.2) 
 
Perpetrator of IPV  
Table 10 describes the relationship of the perpetrators of IPV for the patients who 
provided that information for question two and three. Perpetrators were identified as: “ex-
partner”, “ex-husband”, “partner”, “stranger”, “partner’s best friend”, or “ex-brother-in-law”. Of 
the 54 patients who screened positive for IPV, only 9 patients (16.7%) indicated their 
relationship to the perpetrator of IPV. Of those who indicated their relationship to the 
perpetrator, it was most frequently a former partner who had perpetrated the IPV. 





Perpetrator of IPV Partner 1  
Former Partner 5  
Acquaintance 0  
Stranger 1 
 Other 2 
 Multiple 0  
Total Who Specified 9 
 
Abuse Assessment Screen Data 
Table 11 includes the frequency of each Abuse Assessment Screen question and percent 
of total positive IPV screens. Of note, patients were able to voluntarily respond to any of the five 
questions, so multiple responses are possible for each patient. Question 2 and 3 had follow-up 
questions asking the patient to specify who had perpetrated the violence and how often; very few 
patients responded to these follow-up questions. Only five patients shared how often the violence 
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had occurred. Three patients stated it had happened once, one patient stated it had happened 30 
times, and one patient stated it had happened 34 times. Only one patient specified where they had 
been hit; this patient indicated they had been kicked in the belly by a child with which they 
worked. Only nine patients responded who had perpetrated the violence (Table 10). There is no 
composite score for the AAS scale. If patients indicated yes on any one of the five questions, 
they were considered “positive” for intimate partner violence (McFarland et al., 1996). Fifty-four 
out of 967 participants (5.6%) scored “positive” on this scale. Of those that scored positive, most 
patients only answered Question 1; a large majority of patients (96.3%) responded yes to 
question 1: have you ever been emotionally or physically abused by your partner or someone 
important to you?  
Table 11: Abuse Assessment Screen Data  
Frequency % of total 
54 positive 
screens 
% of total 
respondents 
Question 1: Have you ever been 
emotionally or physically abused by your 
partner or someone important to you? 
52 96.3 5.4 
Question 2: Within the last year, have you 
been hit, slapped, kicked, or otherwise 
physically hurt by someone? 
5 9.3 .5 
Question 3: Since you’ve been pregnant, 
have you been hit, slapped, kicked, or 
otherwise physically hurt by someone? 
1 1.9 .1 
Question 4: Within the last year, has 
anyone forced you to have sexual 
activities”? 
5 9.3 .5 
Question 5: Are you afraid of your partner 
or anyone you listed above?” 








Association between IPV and Maternal and Fetal Health Outcomes  
Table 12 further provides information as to the statistical significance and direction of 
significance of independent variables on IPV before and after exclusion of patients with missing 
delivery data. Table 12 includes the p-values for all chi square tests for association between IPV 
and all independent variables. P-values are included for the analysis performed on the data 
before and after excluding patients with missing delivery data. Variables with a significant p-
value defined as less than .05 are highlighted in red. There are seven total significant variables. 
The significant variables before exclusion are: BMI, STI, psychiatric disorder, birth weight for 
twin A, ultrasound anomaly, insurance provider, and marital status. Significant variables after 
exclusion of patients with missing delivery data are: psychiatric disorder, birth weight for twin 
A, ultrasound anomaly, insurance provider, and marital status. BMI was borderline significant 
before exclusion with a p-value of .010, and BMI became insignificant after exclusion of patients 
with missing delivery data. Additionally, only 42 patients screened positive for a STI before 
exclusion, and STI became insignificant after exclusion. No patients had a bone fracture or head 
trauma diagnosis which explains why no p-value exists for these two variables. Finally, during 
data analysis, variables that are bold had one cell (>20%) with an expected count less than 5 
which meant that a Fisher’s Exact Test result was recorded rather than the Pearson Chi-Square 
Test result.  
Research question two asked: is IPV associated with adverse pregnancy outcomes and/or poor 
birth outcomes? Data from this study show that BMI >25, STI, psychiatric disorder, low birth 
weight, ultrasound anomaly, a non-employer-based insurance provider, and non-married status 




Association Between IPV and Demographic and Birth Outcome Variables 
Table 12 summarizes the direction of significance for six significant variables and eight 
non-significant variables. For the significant variables, to determine direction of significance, 
SPSS crosstabulation results were examined. For example, for patients who tested positive for an 
STI before exclusion, patients with an STI who screened positive for IPV were divided by the 
total number of patients who screened positive for IPV which was 8/51 or 15.7%. Then, patients 
with an STI who screened negative for IPV were divided by the total number of patients who 
screened negative for IPV which was 22/563 or 3.9%. Since 15.7% is greater than 3.9%, it is 
reasonable to conclude that a diagnosis of an STI is associated with IPV. This same reasoning 
was applied to all variables.  
Table 13 provides data from the independent t tests that were conducted on BMI and age. 
An independent t test was conducted to determine if there was a difference in IPV between 
patients with a BMI≥25 and patients with a BMI<25. Results showed that there was a 
statistically significant difference between patients without IPV (n=585, M=29.5, SD=8.2) and 
patients with IPV (n=54, M=32.56, SD=9.02), t (637)= -2.581, p=0.01. The 95% confidence 
interval of the difference was -5.36 - -0.73. Patients with IPV had a slightly higher BMI with a 
mean of 32.6 than patients without IPV whose mean BMI was 29.5.  Next, an independent t test 
was conducted to determine if there was a difference in IPV between patients aged ≥35 years old 
and patients aged <35 years old. There was not a statistically significant difference in mean age 
between patients without IPV (n=587, M=32.08, SD=5.381) and patients with IPV (n=54, 
M=31.72, SD=5.97), t (639)= 0.463, p=0.643, 95% CI for difference= -1.159-1.875). After 
exclusion of patients with missing delivery data, neither BMI nor age were shown to be 
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statistically significant. There was no statistically significant difference between mean BMI in 
patients without IPV (n=411, M=28.996, SD=7.502) and patients with IPV (n=35, M=32.271, 
SD=9.996), p=.066. Similarly, there was also no statistically significant difference in mean age 
between patients without IPV (n=413, M=32.83, SD=5.107) and patients with IPV (n=35, 
M=32.03, SD=6.100), p=0.381.  
 
Table 12: Association Between IPV and Demographic and Birth Outcome Variables  
Before Exclusion (N=967) After Exclusion (N=749)  
+IPV +IPV% -IPV -IPV% P-
value  




          
STI 8/51 15.7 22/563 3.9 0.002 4/35 11.4 18/413 4.4 0.083 
Psychiatric 
Disorder 
21/52 40.4 96/565 17 <0.001 14/35 40 73/413 17.7 0.001 
BWA < 
2.499kg 
10/34 29.4 64/414 15.5 0.035 10/34 29.4 62/411 15.1 0.029 
US 
Anomaly 
11/54 20.1 60/587 10.2 0.019 10/35 28.6 45/413 10.9 0.006 
Non-EBHI 
Insurance 





31/54 57.4 149/585 25.6 <0.001 19/35 52.3 82/413 19.9 <0.001 
Non-Significant Variable 
PTL 4/38 10.5 42/428 9.8 0.781 4/35 11.4 37/413 9 0.547 




7/38 18.4 94/427 22 0.607 7/35 20 90/413 21.8 0.805 
Pain 
Disorder 
2/51 3.9 27/564 4.8 1 2/35 5.7 24/413 5.8 1 
GA 24/36 66.6 325/421 77.2 0.153 24/35 68.6 324/41
3 
78.5 0.178 





GDM 5/54 9.3 85/913 9.3 0.99 3/35 8.6 43/413 10.4 1 
DM 2/54 3.7 22/913 2.4 0.392 2/35 5.7 14/413 3.4 0.36 
 
Table 13: Association Between IPV and BMI and Age 
Variable N Mean Standard 
Deviation 
t df Sig 95% CI for difference in 
mean 
Before Exclusion of Patients with Missing Delivery Data (n=967) 
BMI + no IPV 585 29.52 8.22 
-2.58 637 .010 -5.36 - -0.73 
BMI+ yes IPV 54 32.56 9.02 
Age+ no IPV 587 32.08 5.381 
.463 639 .643 -1.159-1.875 
Age+ yes IPV 54 31.72 5.973 
After Exclusion of Patients with Missing Delivery Data (n=749) 
BMI + no IPV 411 28.996 7.50 
-1.894 37.3 .066 -6.779-0.228 
BMI + yes IPV 35 32.27 9.996 
Age+ no IPV 413 32.83 5.107 
0.878 446 .381 -0.994-2.597 
Age+ yes IPV 35 32.03 6.100 
 
Summary of Results 
The first research question asked: what is the prevalence of IPV in the MFM population at 
Methodist Perinatal Center? According to a survey of 967 patients, the prevalence of IPV in the 
MFM population at Methodist Women’s Hospital is 5.6%. The prevalence of 5.6% is somewhat 
higher than the 2.2% +/- 0.08% (1.4-3%) that was estimated prior to data collection based on 
previous studies. Overall, the fact that this study finds a higher prevalence of IPV than was 
expected highlights how underreported IPV is. The second research question asked: Is IPV 
associated with adverse pregnancy outcomes and/or poor birth outcomes? The variables that 
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were found to be significant after exclusion of patients with missing delivery data are: 
psychiatric disorder, birth weight for twin A, ultrasound anomaly, insurance provider, and 
marital status.  
 
Chapter 5: Discussion 
Summary 
 According to this study, 5.6% of high-risk obstetrics patients at Methodist Women’s 
Hospital have experienced IPV. Results showed that the percent of high-risk pregnant women in 
the Omaha Metro that experience IPV was 2.4% higher than the expected 2.2% (CDC, 2017a). 
The prevalence of 2.2% was chosen as a reference because the PRAMS survey covers both 
physical and psychological violence and is a 50-state survey making it the most generalizable 
data. The prevalence of 5.6% is also higher than the 3.2% statistic cited by Chisholm et al. 
(2017a). However, the prevalence of 5.6% falls within the range of 3.9-8.7% that a majority of 
studies report (Van Parys et al., 2014) but is lower than the prevalence of 3-30% reported by 
Devries et al. (2010). To my knowledge, this is the first study to estimate the prevalence of IPV 
in the MFM population of women. 
The prevalence of 5.6% determined by this study is likely underestimating the true 
prevalence of IPV in this population as IPV is often under-reported due to patients’ fear of 
repercussions due to disclosure or embarrassment (Chisholm et al., 2017a; Hossieni et al., 2017; 
James et al., 2013; Baird, 2015). Moreover, only one percent of domestic violence cases are ever 
reported to the police (James et al., 2013). In this study, 33.7% of patients were not screened due 
to another person’s presence in the room at the time of screening. Clearly, there is a need to 
educate the staff to ensure the importance of the partner not being in the room when delivering 
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the survey so that staff can safely administer the survey for all patients. In addition, even among 
the patients who were screened, studies show patients are very hesitant to report IPV; only 21% 
of women who have experienced IPV actually disclose their experience with IPV to a provider 
(Chisholm et al., 2017b). Many more patients might have screened positive if all patients had 
been screened and if patients felt comfortable disclosing IPV.  
With regard to maternal and fetal health outcomes, data from this study show that BMI 
≥25, STI, psychiatric disorder, low birth weight, ultrasound anomaly, a non-employer-based 
insurance provider, and non-married status are associated with IPV. An association between IPV 
and negative pregnancy outcomes were found which include: overweight BMI, sexually 
transmitted infection, psychiatric disorder, low birth weight, and ultrasound abnormality. 
Further, IPV is associated with non-married patients and patients who self-pay for insurance or 
receive Medicaid. Several of the health outcomes found to be associated with IPV in this study 
corroborate past studies. For example, several studies have found low birth weight to be 
associated with IPV (Chen et al., 2017; Laelago et al., 2017; Chisholm et al., 2017a). Chen et al. 
(2017) found that a NICU admission is associated with IPV. Studies have shown STIs and 
psychiatric disorders to be associated with IPV (Chisholm et al., 2017a; Zachor et al., 2018).  
Chisholm et al. (2017a) report that physical inactivity (which can lead to a higher BMI) is 
associated with IPV. Further, Yakubovich et al. (2018) found that identifying as married is a 
protective factor against IPV and James et al. (2013) report that being single is associated with 
IPV. The finding from these previous studies corroborate the finding from this study that non-
married status is associated with IPV in the MFM population. The only variable found to be 
significant in this study that has not been reported in other studies was ultrasound abnormality. 
This may be because most studies on IPV in pregnancy focus on normal pregnancies that, 
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seemingly, would not have an ultrasound abnormality. This study included ultrasound 
abnormality as maternal fetal medicine specialists are more likely to encounter patients whose 
pregnancies contain ultrasound abnormalities. This finding may be new and subject for future 
research. For all of these patients experiencing IPV, their future health trajectories will likely be 
negatively affected by IPV. Based on this study, it is clear that it is vitally important to screen all 
patients- especially high-risk pregnant patients- for IPV.  
With regard to risk factors, research shows young women, typically under age 25, are at 
higher risk for IPV (Yakubovich et al., 2018). However, this study did not show that age was 
statistically significant. For this study, patients of advanced maternal age are more clinically 
significant in the MFM population than being a younger age. When it became necessary to split 
patient ages into two groups for data analysis, the age of 35 was chosen as the delineating point 
because being 35 or older is defined as advanced maternal age. Additionally, the mean age for 
patients in this study was 32 which also justified an age cut-off of 35. Perhaps if the age cutoff 
had been lower, that might have shown significance as younger women have been shown to be at 
higher risk for IPV than older women. Further studies could create a lower age cutoff to examine 
this. Also, Chisholm et al. (2017a) state that certain health disparities according to race, 
ethnicity, education, income, and age are associated with IPV. Of these variables, this study only 
showed a non-employer-based insurance provider to be statistically significant. In the United 
States, since most people rely on their job for health insurance (Berchick et al., 2019), health 
insurance can be used as a surrogate for employment and, thus, socioeconomic status. Since 
having non-employer-based health insurance (self-pay or Medicaid) was statistically significant 
in its association to IPV, it stands to reason that patients of lower socioeconomic status are at 
higher risk for IPV in this study population. Additionally, as this study population was not very 
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diverse in ethnicity, race, or language spoken, future studies would benefit from a more diverse 
population. If this study were to include patients from other health centers in Omaha that have a 
larger percentage of a diverse patient population, that would provide more data about the patient 
population of the Omaha Metro Area as a whole.  
Additionally, studies have found that abuse before pregnancy is associated with IPV 
(James et al., 2013). Among the patients in this study who screened positive for IPV, 96.3% of 
them screened positive for Question 1 of the AAS which asks if a patient has ever been 
emotionally or physically abused by a partner or someone important to them. This indicates that 
a majority of the patients in this study that screened positive for IPV had experienced IPV 
sometime during their life prior to or during their current pregnancy. The results of this study 
seem to support prior findings that abuse before pregnancy is associated with IPV.  Another risk 
factor for IPV is having experienced violence by a family member which is an adverse child 
event (Ludermir et al., 2017). While only two patients of this cohort indicated their former IPV 
exposure was from a family member, that is not clinically insignificant. This finding highlights 
the need for providers to holistically approach patients and further understand how the lifespan 
affects a patient- with particular focus on how exposure to adverse childhood events can impact a 
person later in life. 
Furthermore, some of the effects of IPV that have been reported in the literature are bone 
fracture, laceration, head trauma, STI, pain disorder, and psychiatric disorder (Chisholm et al., 
2017a). Of these effects, STI and psychiatric disorder were statistically significant in this study. 
It might be important for staff and providers at this clinic to take these findings in consideration 
when working with patients with STIs and/or psychiatric disorders as they may be experiencing 
IPV. Adverse fetal outcomes that have been shown to be related to IPV are small for gestational 
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age, preterm birth, and low birthweight (Chisholm et al., 2017a). Specifically, many studies have 
shown low birthweight to be associated with IPV (Chisholm et al., 2017a; Chen et al., 2017; 
Laelago et al., 2017). Results from this study indicate that IPV is associated with infants with a 
low birth weight. This is significant because low birthweight infants are at risk for a multitude of 
health issues (American Academy of Pediatrics, 2017). For example, having an infant with low 
birth weight and its effects could place stress on the mother and potentially strain the mother’s 
relationship with her partner and exacerbate any IPV that may be occurring. One study found 
that mothers who have infants born with a very low birth weight experience stress due to related 
complications; this stress negatively affects mothers, families, and infants (Helle et al., 2018). 
When considering low birth weight infants as similar to very low birth weight infants, it is 
possible that mothers with low birth weight infants would also experience stress, thus, negatively 
affecting the mother, infant, and family structure. Further, Ellis et al. (2008) found that after birth 
women who had experienced IPV continue to report higher levels of stress and less partner 
support than women who do not experience IPV. They found that women who have experienced 
IPV seek healthcare more often for their infants than women who have not experienced IPV; the 
study hypothesized that the IPV may result in the infants and their mothers experiencing more 
illness. Any of this additional stress could exacerbate any IPV that might be occurring. 
Strengths and Limitations 
One strength of this study is that through the partnership with physicians at Methodist 
Perinatal Center, the full five-question abuse assessment screen was implemented into the 
electronic health record for the entire Methodist Women’s Hospital system. As of January 2019, 
all patients receiving care for a first obstetrics visit are to be screened for IPV with the AAS. 
Prior to implementing the AAS, the IPV screen was only a one-question, unvalidated screen. 
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Another strength of the study is the choice of the screening instrument. The AAS is short which 
decreases survey fatigue. Also, the survey includes various forms of abuse including both 
physical and psychological abuse which not all IPV screening instruments do. Further, the AAS 
includes a question specifically about pregnancy; not all IPV surveys include a question about 
pregnancy. Additionally, this study is one of the first to examine IPV in the MFM population, 
providing valuable groundwork for further work on IPV in this patient population.  
There are several limitations of this study. First, it is unclear if patients who only 
presented for an ultrasound were excluded from the initial sample. Support staff ran an analysis 
of every patient that was seen for a first OB visit within the study time parameters, but some 
visits that were for ultrasound-only might have been included unintentionally which may have 
contributed to the 218 patients that have missing delivery data. Second, confounding factors 
likely made a difference in patients’ understanding of the survey questions. The confounding 
variable is patient understanding of “abuse” or “emotional abuse” which possibly resulted in 
underreporting. Also, two patients who screened positive for IPV indicated that their exposure 
was due to their profession being around children who kicked them; while that circumstance 
technically answers the AAS questions, that response does not fall under the definition of IPV or 
interpersonal abuse. In this way, those two patients were false positives. While not a large 
number, that still indicates there was some confusion on patients’ behalf regarding the purpose of 
the questions. This points to either the need for more training for the staff delivering these 
questions or the need to choose an IPV survey instrument that better clarifies the screening 
questions. Also, the AAS allows for patients to select options “stranger” and “acquaintance” for 
the identity of the perpetrator of the IPV. Neither strangers or acquaintances fall under the 
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definition of an intimate partner. In this way, the AAS includes both IPV and interpersonal 
violence, which is a consideration for future studies when selecting a survey instrument. 
Further, another limitation is the inability to screen patients alone. If a woman was not 
able to be screened alone, the staff were instructed not to administer the survey questions for the 
patient’s safety which resulted in a smaller sample size. There are three likely possibilities for 
patients not being able to be screened alone: the patient might have wanted another person in the 
room with them, persons accompanying the patient might have insisted on accompanying the 
patient and disregarded the request of staff members to speak to the patient alone, and/or staff 
members might have failed to provide clear instructions to the patient and support person or did 
not have the skills to separate the patient from the person. Any one of these or other reasons 
could have contributed to a third of patients not being able to be screened alone. However, even 
if patients were able to be screened alone, research shows that patients often do not feel safe 
reporting IPV (Chisholm et al., 2017a; Hossieni et al., 2017; James et al., 2013; Baird, 2015; 
Fletcher et al., 2016). For example, in this study 54 patients screened positive for IPV. However, 
six other patients who did not screen positive for IPV in this study had diagnosis codes in their 
chart indicating a history of IPV even to the point that one patient requested a cesarean delivery 
due to the patient’s past IPV-related trauma. 
With 33.7% of patients not being screened, there is improvement to be made to ensure 
staff are able to separate patients from support persons (often partners) to conduct the survey 
confidentially. Another issue indicating a need to educate the support staff is that some staff were 
still using the previously-used IPV screen. Those patients had to be excluded, decreasing the 
sample size of this study. Educating the support staff on IPV and the AAS might help alleviate 
this confusion. Staff also weren’t trained on how to provide feedback to patients’ questions about 
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the questionnaire. Past studies have shown that training nursing and support staff about IPV and 
the screening survey is well received (Burmele et al., 2018). Perhaps, the staff at Methodist 
Perinatal Center can undergo training on IPV and the AAS which might lead to an increase IPV 
screening rate. Training of providers has also been shown to increase their communication with 
patients about IPV; in the future, providers at Methodist Perinatal Center could also undergo IPV 
training (Zachor et al., 2018).  
Further, due to personnel constraints, a screen during subsequent trimesters was not 
possible during this research study which limited this study’s ability to capture all patients who 
experienced IPV during the entirety of their pregnancy. However, future research projects could 
include screens during each pregnancy trimester to ensure that patients are not being missed if 
they experience IPV later in their pregnancy. Also, certain demographic information such as 
gender identity and sexual orientation are not included as the electronic health record utilized 
does not provide this information. As we are unable to collect this information at this time, this is 
an area for future research projects to examine. Additionally, there was no plan in place for the 
patients who screened positive other than following clinical guidelines and providing local 
resources- namely information about the Women’s Center for Advancement, the main resource 
center for people who have experienced interpersonal violence in the Omaha Metro Area. In the 
future, a more robust plan should be in place in the event of a positive IPV screen. Another 
limitation is that staff had not been trained in the concepts of trauma-informed care; this is 
something which the clinic could pursue in the future. 
Moreover, there are several limitations to a non-probability sampling method. Non-
probability sampling methods are not as robust as probability sampling methods. While it is the 
easiest form of sampling to complete, convenience sampling creates the potential for bias within 
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the data collected. Since convenience samples are not randomized, there is no way to reduce bias 
within the sample. Since the sample data is only coming from one clinic, there is no way to 
generalize the data to other populations. Because there is no randomization within convenience 
sampling, that makes it a weaker sampling method. Future studies can an attempt to incorporate 
more robust sampling methods. Further, only one hospital system was sampled due to time 
constraints and personnel constraints. Including other hospitals in the study in an effort to 
increase generalizability of data would require participation and cooperation from multiple 
departments and personnel. 
Additionally, future research could include a mixed methods study by gathering 
qualitative data from interviews with patients who screen positive and staff who administer the 
survey. This could provide valuable information that could help guide decision-making regarding 
intervention strategies for future patients. Additionally, another area for future research would be 
to examine the difference in proportion screened for IPV before the Abuse Assessment Screen 
was incorporated into the EMR at Methodist Perinatal Center and after the incorporation of the 
screen. Prior to this study, the Methodist Perinatal Center included a one-question unvalidated 
screen for IPV. After incorporating a more robust and standardized screening survey and 
procedure, it is hypothesized that there would be an increase in screening after incorporation of 
the Abuse Assessment Screen into the EMR. This question highlights the effects of various 
forms of EMR on screening for any health condition. Depending on the hospital system and 
which EMR a hospital system chooses to use, there may be a difference in the robustness of 




 Data from this study indicates that more patients than expected are experiencing IPV at 
Methodist Women’s Hospital as this study found that IPV was 3.4% higher than the expected 
2.2% (CDC, 2017a). Often, the IPV discourse focuses on populations that are known to be at risk 
for IPV. The demographics of the patient population at Methodist Perinatal Clinic was shown to 
be largely white, English-speaking, non-Hispanic, employed, married, and with employer-based 
health insurance which is not largely representative of the populations who are known to be at 
greater risk for IPV. One takeaway from this study is that IPV can and does exist in all patient 
populations- even among patients who might be among the demographics that carry less risk 
factors for IPV such as patients who are white, English-speaking, non-Hispanic, employed, and 
married. Again, it is clear that it is vitally important that all patients be screened for IPV. There is 
always the potential to encounter a patient who has experienced IPV and to intervene and 
improve outcomes. 
Generalizability 
This study took place at one clinic in Omaha, NE. Unfortunately, the Methodist Perinatal 
Center is not representative of the entire Omaha Metro Area population as the demographic 
make-up of patients at Methodist Perinatal Center does not reflect the demographic make-up of 
the Omaha Metro Area. Including more hospital systems in future studies would help to diversify 
the patient population to make it more generalizable to the Omaha Metro Area. However, even 
then that would not make it generalizable to the overall population of the United States. Future 
studies could consider including hospitals from multiple states to ensure the greatest 
generalizability. This often requires funding and can be logistically challenging, but it would 
provide invaluable information about how many high-risk obstetrics patients are experiencing 




The research question for this study was born out of a passion for investigating intimate 
partner violence among high-risk pregnant patients. As IPV has not been thoroughly studied 
among the high-risk pregnant population, a quantitative assessment of the prevalence of IPV in 
the MFM population was helpful before attempting a qualitative in-depth analysis of the 
population. Now that quantitative data has been obtained, qualitative data from patients who 
screen positive for IPV could be obtained in the future that would further inform IPV 
intervention strategies. Further, it is evident from the findings of this study that the life course 
theory can inform thinking about IPV in the setting of pregnancy- including high-risk pregnancy. 
Pregnancy is an important transition in the lives of many women that has the potential to either 
positively or negatively alter a woman’s life course trajectory and, possibly, her future 
offspring’s trajectory. Further, if a woman experiences IPV during her pregnancy, that more than 
likely negatively affects her trajectory. The maternal fetal medicine patient population is already 
at high risk of experiencing a negative change in their health trajectory after pregnancy. Thus, an 
understanding of intimate partner violence is vitally important for all health care personnel 
caring for high-risk pregnant patients. 
 
Literature Cited 
1. A.A.P., C. O. F. A. N., & ACOG, C. O. O. P. (2017). Guidelines for perinatal care. Retrieved 
from https://ebookcentral.proquest.com 
2. Anyikwa, V. A. (2016). Trauma-Informed Approach to Survivors of Intimate Partner Violence. 




3. Bailey, B. (2010). Partner violence during pregnancy: prevalence, effects, screening, and 
management. International Journal of Womens Health, 183–197. doi: 10.2147/ijwh.s8632 
4. Baird, K. (2015). Women's lived experiences of domestic violence during pregnancy (2). The 
Practicing Midwife, 28. doi: 10.1016/j.wombi.2015.07.035 
5. Berchick, Edward R., Jessica C. Barnett, and Rachel D. Upton Current Population Reports, P60-
267(RV), Health Insurance Coverage in the United States: 2018, U.S. Government Printing 
Office, Washington, DC, 2019. 
6. Bermele, C., Andresen, P. A., & Urbanski, S. (2018). Educating Nurses to Screen and Intervene 
for Intimate Partner Violence During Pregnancy. Nursing for Women's Health, 22(1), 79-86. 
doi:10.1016/j.nwh.2017.12.006 
7. Breiding M. J.,Smith S. G., Basile, K. C., Walters M. L., Chen J., Merrick M.T. Prevalence and 
characteristics of sexual violence, stalking, and intimate partner violence victimization-national 
intimate partner and sexual violence survey, United States, 2011. Available at: 
https://www.cdc.gov/mmwr/preview/mmwrhtml/ss6308a1.htm. 
8. Brown, J. B., Lent, B., Brett, P. J., Sas, G., & Pederson, L. L. (1996). Development of the 
Woman Abuse Screening Tool for use in family practice. Family Medicine, 28(6), 422–428. 
9. Casanova, R., Chuang, A., Goepfert, A. R., Hueppchen, N. A., Weiss, P. M., Beckmann, C. R. 
B., … Smith, R. P. (2019). Beckmann and Ling's Obstetrics and Gynecology. Philadelphia: 
Wolters Kluwer. 
10. Centers for Disease Control and Prevention. (2017a). Prevalence of Selected Maternal and Child 
Health Indicators for all PRAMS sites, Pregnancy Risk Assessment Monitoring System 




11. Centers for Disease Control and Prevention (2017b). Violence Prevention. Retrieved August 29, 
2018, from https://www.cdc.gov/violenceprevention/intimatepartnerviolence/definitions.html 
12. Chen, P., PhD. (2017). Birth Outcomes in Relation to Intimate Partner Violence. Journal of the 
National Medical Association, 109(4), 238-243. 
13. Chisholm, C. A., Bullock, L., Ferguson, J. E. (2017a). “Intimate partner violence and pregnancy: 
epidemiology and impact.” American Journal of Obstetrics and Gynecology, 141-144. 
14. Chisholm, C. A., Bullock, L., Ferguson, J. E. (2017b). “Intimate partner violence and pregnancy: 
screening and intervention.” American Journal of Obstetrics and Gynecology, 145-149. 
15. Devries, K. M., Kishor, S., Johnson, H., Stöckl, H., Bacchus, L. J., Garcia-Moreno, C., & Watts, 
C. (2010). Intimate partner violence during pregnancy: analysis of prevalence data from 19 
countries. Reproductive Health Matters, 18(36), 158–170. doi: 10.1016/s0968-8080(10)36533-5 
16. Ellis, K. K., Chang, C., Bhandari, S., Ball, K., Geden, E., Everett, K. D., & Bullock, L. (2008). 
Rural Mothers Experiencing the Stress of Intimate Partner Violence or Not: Their Newborn 
Health Concerns. Journal of Midwifery & Womens Health, 53(6), 556–562. doi: 
10.1016/j.jmwh.2008.05.012 
17. Eunice Kennedy Shriver National Institute of Child Health and Human Development. (2017). 
Retrieved December 09, 2018, from https://www.nichd.nih.gov/ 
18. Fletcher, Tifani R.; Clements, Andrea D.; and Bailey, Beth (2016) "Identifying Intimate Partner 
Violence during Pregnancy in Prenatal Care Settings," International Journal of Health Sciences 
Education, 3(1). 
19. Gazmararian, J. A. (1996). Prevalence of Violence Against Pregnant Women. JAMA: The 




20. Helle, N., Barkmann, C., Ehrhardt, S., & Bindt, C. (2018). Postpartum posttraumatic and acute 
stress in mothers and fathers of infants with very low birth weight: Cross-sectional results from a 
controlled multicenter cohort study. Journal of Affective Disorders, 235, 467–473. doi: 
10.1016/j.jad.2018.04.013 
21. Hossieni, V. M., Toohill, J., Akaberi, A., HashemiAsl, B. (2017). Influence of intimate partner 
violence during pregnancy on fear of childbirth. Sexual & Reproductive Healthcare, 17-23. 
22. IBM SPSS Statistics for Macintosh, IBM SPSS Statistics Subscription build number 1.0.0.1327. 
23. James, L., Brody, D., & Hamilton, Z. (2013). Risk Factors for Domestic Violence During 
Pregnancy: A Meta-Analytic Review. Violence and Victims, 28(3), 359-380. doi:10.1891/0886-
6708.vv-d-12-00034 
24. Kotch, J. (2013) Maternal and Child Health. Burlington, MA: Jones & Bartlett Learning. 
25. Laelago, T., Belachew, T., & Tamrat, M. (2017). Effect of intimate partner violence on birth 
outcomes. African Health Sciences, 17(3), 681. doi:10.4314/ahs.v17i3.10 
26. Lee, S., & Lee, E. (2017). “Predictors of intimate partner violence among pregnant women.” 
International Journal of Gynecology and Obstetrics, 159-163. 
27. Ludermir, A. B., Araújo, T. V., Valongueiro, S. A., Muniz, M. L., & Silva, E. P. (2017). 
Previous experience of family violence and intimate partner violence in pregnancy. Revista De 
Saúde Pública, 51. doi:10.11606/s1518-8787.2017051006700 
28. McFarlane, J., Parker, B., Soeken, K., & Bullock, L. (1992). Assessing for Abuse During 
Pregnancy: Severity and Frequency of Injuries and Associated Entry Into Prenatal Care. Journal 
of American Medical Association, 267(23), 3176-3178. 
 
Larsen 47 
29. Miller-Graff, L. E., Ahmed, A. H., & Paulson, J. L. (2018). Intimate Partner Violence and 
Breastfeeding Outcomes in a Sample of Low-Income Women. Journal of Human 
Lactation, 34(3), 494-502. doi:10.1177/0890334418776217  
30. O’Reilly, R., Beale, B., & Gillies, D. (2010). Screening and Intervention for Domestic Violence 
During Pregnancy Care: A Systematic Review. Trauma, Violence, & Abuse, 11(4), 190–201. doi: 
10.1177/1524838010378298 
31. QuickFacts. (2017). United States Census Bureau. Retrieved from 
https://www.census.gov/quickfacts/fact/table/omahacitynebraska,US/PST045217  
32. Society for Maternal Fetal Medicine. (2018). What is a Maternal Fetal Medicine Specialist. 
Retrieved August 29, 2018, from https://www.smfm.org/members/what-is-a-mfm 
33. Sohal, H., Eldridge, S., & Feder, G. (2007). The sensitivity and specificity of four questions 
(HARK) to identify intimate partner violence: a diagnostic accuracy study in general 
practice. BMC Family Practice, 8(1). doi: 10.1186/1471-2296-8-49. 
34. Substance Abuse and Mental Health Services Administration. (2014). SAMHSA’s concept of 
trauma and guidance for a trauma-informed approach. HHS Publication No. (SMA) 14-4884. 
Rockville, MD: Substance Abuse and Mental Health Services Administration. 
35. Van Parys, A.-S. V., Deschepper, E., Roelens, K., Temmerman, M., & Verstraelen, H. (2017). 
The impact of a referral card-based intervention on intimate partner violence, psychosocial 
health, help-seeking and safety behaviour during pregnancy and postpartum: a randomized 
controlled trial. BMC Pregnancy and Childbirth, 17(1). doi: 10.1186/s12884-017-1519-x 
36. Parys, A.-S. V., Verhamme, A., Temmerman, M., & Verstraelen, H. (2014). Intimate Partner 




37. What is a high-risk pregnancy? (2017). Eunice Kennedy Shriver National Institute of Child 
Health and Human Development. Retrieved from https://www.nichd.nih.gov/health/topics/high-
risk 
38. Webster, J., & Holt, V. (2004). Screening for Partner Violence: Direct Questioning or Self-
Report. Obstetrics & Gynecology, 103(2), 299–303. doi: 10.1097/01.aog.0000110245.83404.3d 
39. Yakubovich, A. R., Stöckl, H., Murray, J., Melendez-Torres, G. J., Steinert, J. I., Glavin, C. E., 
& Humphreys, D. K. (2018). Risk and Protective Factors for Intimate Partner Violence Against 
Women: Systematic Review and Meta-analyses of Prospective–Longitudinal Studies. American 
Journal of Public Health, 108(7). doi:10.2105/ajph.2018.304428 
40. Zachor, H., Chang, J. C., Zelazny, S., Jones, K. A., & Miller, E. (2018). Training reproductive 
health providers to talk about intimate partner violence and reproductive coercion: An 
exploratory study. Health Education Research, 33(2), 175-185. doi:10.1093/her/cyy007 
Supervision and Facilities 
This capstone project has been supervised by Dr. Dahlke, and data was collected from Methodist 
Women’s Hospital. Dr. Lynette Smith was consulted for assistance with statistical analysis. Dr. 
Rajaram and Dr. Carl Smith have provided additional advice and guidance throughout the 
project. 
Human Subjects 
This project required an IRB from both UNMC and Methodist. Dr. Dahlke assisted with the 
Methodist IRB (Appendix B), and the student obtained UNMC IRB approval (Appendix C). IRB 
approval at both UNMC and Methodist was obtained prior to data collection. 
















NEBRASKA'S HEALTH SCIENCE CENTER Office of Regulatory Affairs (ORA)






TITLE OF PROPOSAL: Prevalence of Intimate Partner Violence Among the Maternal-Fetal Medicine Population
DATE OF REVIEW: 09/20/2019
DATE OF FINAL ACCEPTANCE:  VALID UNTIL: 09/20/2020
The UNMC IRB has completed its review of the above-titled external protocol. Please be advised that the UNMC
IRB has accepted approval from the Methodist IRB under the provisions of 45 CFR 46.114.
It is understood that Methodist IRB is responsible for oversight of the above-titled research project in accordance
with HHS regulations at 45 CFR 46 and FDA regulations at 21 CFR 50, 56 as applicable. Such oversight includes:
1) continuing review no less often than annually, 2) approval of any protocol amendments, 3) reporting to the
Office for Human Research Protections (OHRP), and FDA as applicable, 4) unanticipated problems involving risk
to subjects or others, and 5)  serious and continuing non-compliance, as well as suspensions. Should any
reports be filed with OHRP and/or FDA, the UNMC IRB should be provided with copies of such correspondence.
Finally, please be advised that acceptance by the UNMC IRB of the Methodist IRB approval is valid for a period of
five years from the initial date of review. If the study continues beyond the five year period, the project must be
resubmitted in order to maintain an active status.
On Behalf of the IRB,
Signed on: 2019-09-20 14:52:00.000
Gail Kotulak, BS, CIP
IRB Administrator III
Office of Regulatory Affairs
 
Academic and Research Services Building 3000 / 987830 Nebraska Medical Center / Omaha, NE 68198-7830
402-559-6463 / FAX: 402-559-3300 / Email: irbora@unmc.edu / http://www.unmc.edu/irb
